This White Paper is intended for a broad, cross-sector audience, including:

• Foundations and patient organizations

• Academic medical centers and hospital leadership

• Biotech and life sciences companies

• Impact investors, venture philanthropy funds, and family offices

• Policymakers, regulators, and ecosystem partners

While grounded in the realities of childhood cancer, the goal of this document is to educate beyond the pediatric oncology community—highlighting the structural challenges and inefficiencies in pediatric drug development and presenting a scalable, evidence-based model relevant across healthcare, mission-aligned capital, and innovation.

Interested in reading the full paper? Fill the form below to receive it in your inbox.